Vontobel Holding Ltd.,
First Horizon Advisors Inc., and
GF Fund Management CO. LTD. have increased their stakes in
Regeneron Pharmaceuticals. On the other hand,
Braun Stacey Associates Inc. and
Robeco Institutional Asset Management B.V. amongst others have decreased their holding. The
US FDA has provided approval for Regeneron's
blood cancer therapy and its joint venture with
Sanofi's Dupixent, a promising development.
RedJay Asset Management Inc. and
Global Assets Advisory LLC initiated positions in the company. Despite a downgrade by
UBS,
JP Morgan revised Regeneron's price target emphasizes value in the stock. Regeneron's
Lynozyfic received accelerated
FDA approval for heavily pre-treated multiple myeloma. The company has also introduced a $200M
patient assistance match program for eye disease treatments. Dishearteningly, the stock was dropped from
Russell 3000 Growth Index, and a Sanofi-linked setback caused the stock to plummet 19%. Nevertheless, the future growth prospects bolstered by strategic moves in rare disease treatment and potential entry into the weight loss market can outweigh the short-term challenges.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 25 Mar 2025 07:00:00 GMT to Sat, 05 Jul 2025 22:45:46 GMT -
Rating 3
- Innovation 6
- Information 7
- Rumor -2
